Related Experiment Video
Updated: May 8, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Multimodal tumor suppression by METTL3 gene knockdown in melanoma and colon cancer cells
Arezoo Bazargani1, Masoumeh Fakhr Taha1, Bahram Mohammad Soltani2
1Department of Stem Cells and Regenerative Medicine, Institute for Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Blvd., P.O. Box 14965-161, Tehran, Iran.
Abstract:
METTL3, an m6A methyltransferase, is integral to the regulation of messenger RNA (mRNA) biogenesis, degradation, and translation through the N6-methyladenosine (m6A) modification. Alterations in m6A homeostasis have been implicated in the development, progression, invasion, and metastasis of certain cancers. The present research aims to examine the consequences of METTL3 knockdown using short hairpin RNA (shRNA) on the proliferation and invasive capabilities of human colorectal and melanoma cancer cell lines. A specific shRNA against METTL3 mRNA was designed and inserted into an expression vector. Highly invasive colorectal cancer cell line SW480 and melanoma cell line A375 were cultured and transfected by METTL3-shRNA and scramble-control vectors and kept under culture condition for 2 weeks. The cells were harvested for analysis of gene expression by quantitative polymerase chain reaction (qPCR), invasion assay using three-dimensional (3D) spheroid assay and cell cycle and apoptosis analyses. In the METTL3-shRNA transfected cells, the expression of METTL3, VIM, SNAI1, SNAI2, ZEB1, CDH1, and TGFB1 genes were downregulated significantly compared with the scramble-control transfected cells. Expression of b-catenin, N-cadherin, vimentin, ZEB1, pro- and active MMP2, OCT4A, SOX2, and MYC proteins were also downregulated following METTL3 knockdown. Transfection by METTL3-shRNA reduced proliferation rate of the cells and increased the apoptotic rate significantly. Both migration and invasion rate of the cancer cells transfected with METTL3-shRNA were significantly decreased. These findings highlight the pro-oncogenic function of METTL3 in colorectal and melanoma cancer cells, indicating that inhibiting METTL3 could be a promising approach for tumor suppression across multiple cancer types; nonetheless, further investigation is essential to confirm these observations.
Insights
Inhibiting METTL3 (methyltransferase-like 3) significantly reduced proliferation and invasion in colorectal and melanoma cancer cells. This suggests METTL3 plays a pro-oncogenic role, making it a potential target for cancer therapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- METTL3 is a key methyltransferase regulating mRNA modifications (N6-methyladenosine).
- Dysregulation of m6A homeostasis is linked to cancer development, progression, and metastasis.
- METTL3's specific role in colorectal and melanoma cancer requires further elucidation.
Purpose of the Study:
- To investigate the functional impact of METTL3 knockdown on colorectal and melanoma cancer cell lines.
- To assess the effects of METTL3 inhibition on cancer cell proliferation, invasion, migration, and apoptosis.
Main Methods:
- Short hairpin RNA (shRNA) was used to knockdown METTL3 in SW480 (colorectal) and A375 (melanoma) cell lines.
- Quantitative PCR (qPCR) analyzed gene expression changes.
- Three-dimensional (3D) spheroid invasion assays assessed invasive capabilities.
- Cell cycle and apoptosis analyses were performed.
Main Results:
- METTL3 knockdown significantly downregulated key genes (VIM, SNAI1, SNAI2, ZEB1, CDH1, TGFB1) and proteins (beta-catenin, N-cadherin, vimentin, MMP2, OCT4A, SOX2, MYC).
- Proliferation rates decreased, while apoptosis rates increased in METTL3-silenced cells.
- Cancer cell migration and invasion were significantly reduced following METTL3 knockdown.
Conclusions:
- METTL3 exhibits a pro-oncogenic function in colorectal and melanoma cancer cells.
- Inhibiting METTL3 demonstrates potential as a therapeutic strategy for tumor suppression.
- Further research is warranted to validate these findings for broader cancer applications.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019